Pharma

Your Article Summary

See Latest Articles

Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Cephalon, 10/27/09

Cephalon, Inc. and BioAssets Development Corporation, a privately held biopharmaceutical company, announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC. Under the terms of the option agreement, Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the acquisition. BDC stockholders could also receive additional future payments related to regulatory and sales milestones.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Human genome sciences and bioinvent announce collaboration to co-develop and commercialize therapeutic antibodies
Human Genome Sciences, 03/12/10

SickKids to help create new pediatric centre in Qatar
Canadian Healthcare Technology, 03/12/10

Siemens to develop HealthVault in Germany
Canadian Healthcare Technology, 03/12/10

 See all of M&A/Partnerships

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New Insights Into Open Innovation
PharmExec, 03/12/10

Harnessing a Maverick Talent
PharmExec, 03/12/10

$1.5 million for brain imaging at Sunnybrook
Canadian Healthcare Technology, 03/12/10

 See all of Research & Development